This study is not yet accepting patients
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California
- Dates
- study startedestimated completion
- Principal Investigator
- by Elaine Ku, MD
Description
Summary
Keywords
Eligibility
Location
Lead Scientist at UCSF
- Elaine Ku, MD
The global context of my research program focuses on understanding differences in the epidemiology, clinical management, and outcomes of children versus adults with kidney disease and the conduct of clinical trials to test interventions (such as blood pressure control) that will improve survival of patients with kidney disease.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- University of California, San Francisco
- ID
- NCT04473924
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated